The latest news from UKI2S and our portfolio companies
23rd October 2017
A Smart Textiles Technology Developed at the National Physical Laboratory.
6th October 2017
UK Innovation & Science Seed Fund has closed its first investment (to be announced soon) originating from the Fund’s participation in the Innovate UK (IUK) Investment Accelerator pilot…
14th September 2017
Investing in the UK life science ecosystem.
12th July 2017
Eco-friendly engineering biology start-up revolutionising dyeing process.
10th July 2017
UK Innovation & Science Seed Fund is proud to sponsor the UK’s first Engineering Biology accelerator programme announced by Bio-start.
7th July 2017
Chemical detection innovator secures access to global markets.
6th July 2017
As you may have read in our Chairman Ian Taylor’s recent blog “For the Love of Spinouts,” you’ll know that UKI2S hosted an event with the Innovate UK Catapult network…
8th June 2017
UKI2S portfolio update: New investments in Linear Diagnostics & Nemesis Bioscience + significant advancements for Quethera & Cytox
25th May 2017
With the increasing presence in our lives of robotics, artificial intelligence, genomics and a host of new technologies changing the way we fight diseases…
23rd May 2017
Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data at the 2017 Association for Research in Vision and Ophthalmology (ARVO)…
8th May 2017
Nemesis Bioscience today announced the successful completion of its latest funding round, bringing total seed funds raised to more than £700,000…
4th May 2017
British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end.
19th April 2017
UK Innovation & Science Seed Fund is partnering with Innovate UK’s £8.5 million Investment Accelerator pilot to fund innovative high-risk projects and invest in companies that have real potential for growth in…
24th March 2017
Spinout developing novel hand-held reader to help in the fight against antibiotic resistance.
25th January 2017
Researchers looking into retinitis pigmentosa have been able to improve vision in rats using the CRISPR-Cas9 gene editing technology.
16th January 2017
Plants get damaged by the sun just like people, and they protect themselves from sun damage by a process known as photoprotection…
9th January 2017
UKI2S Investment Manager Oliver Sexton will chair the Innovation Investment panel to provide an insight into the opportunities available for startups.
6th December 2016
Scientists in China have become the first in the world to administer CRISPR-Cas9-edited cells to humans.
28th November 2016
Early-stage venture fund key in bridging gap between UK research and commercialisation. Fund aims to turn UK scientific ‘world’s first’…
17th November 2016
Alaska Airlines and the Washington State University-led Northwest Advanced Renewables Alliance (NARA) made history on 14 November 2016 by flying…
9th November 2016
CellCentric is developing first in class drug compounds against a key regulator of cancer.
7th November 2016
Two UKI2S portfolio companies recognised amongst world’s most innovative companies.
10th October 2016
Collaboration to generate tumor targeting drug conjugates and immuno-oncology therapeutics.
SynbiCITE and UK Innovation & Science Seed Fund today announce that Sir Richard Sykes, Chairman of the Royal Institution of Great Britain, Chairman of…
© UKI2S and Future Planet Capital (Ventures) Limited. All Rights Reserved. UKI2S is managed by Future Planet Capital (Ventures) Limited which is Authorised and Regulated in the UK by the Financial Conduct Authority FRN 148549. Registered in England and Wales. Company Number 2500898. Registered Address: Future Planet Capital (Ventures) Limited, 1 Scott Place, 2 Hardman Street, Manchester, M3 3AA.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.